Au­rinia eye drug falls short in im­prov­ing tol­er­a­bil­i­ty ver­sus Resta­sis, but beats on ef­fi­ca­cy

Al­ler­gan’s best-sell­ing dry eye drug Resta­sis was de­vel­oped af­ter the im­muno­sup­pres­sant was orig­i­nal­ly shown to en­hance tear pro­duc­tion in dogs. Sim­i­lar­ly, Cana­da’s Au­rinia Phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.